News Releases

Jan. 5, 2001

Sumitomo Pharmaceuticals Subscribes to Gene Logic's GeneExpress® Database

Sumitomo Pharmaceuticals Co., Ltd. announced today that on December 26, 2000 it became the first in Japan to subscribe to portions of the GeneExpress® Suite from Gene Logic Inc. (MD, USA), a leading provider of gene expression information.

Under the terms of the GeneExpress® subscription, Sumitomo Pharmaceuticals will have access to two elements of the genomic venture's database: gene expression and associated information, and a reference library of toxicity markers.

The gene expression database contains broad-ranging information, including fluctuations in expression in normal and diseased tissues and cultured cells of human and animal genes. The toxicity marker reference library provides data on gene expression when toxic substances are administered. Built on DNA chip and advanced bio-informatics technologies, Gene Logic's gene expression information database is reputed to be one of the best in the world.

Sumitomo Pharmaceuticals shares common DNA chip technology with Gene Logic, and plans a systematic integration of the partner's data with its own for genome-based drug discovery research.

Sumitomo Pharmaceuticals subscribed to Incyte's gene sequence database in November 2000. The company hopes the new tie-in with Gene Logic will provide further momentum for its genome-based drug discovery research, improving the overall efficiency of the company's investigations into new drugs.

With top priority focused on genome-based research, Sumitomo Pharmaceuticals has been strengthening its capabilities in this regard. Led by the Genomic Science Laboratories, established in October 2000 jointly with Sumitomo Chemical Co., Ltd., it has also been working in association with other laboratories specializing in drug discovery to create new drugs with distinctive concepts. Sumitomo Pharmaceuticals is focusing on the identification of innovative drug targets and their functional analysis, as well as action mechanism analysis of drug candidate compounds and the prediction of adverse events caused by these compounds.